All News
Zara Izadi presents @rheum_covid data on machine learning algorithms to predict ARDS in RMD patients with COVID. Gradient boosting machine had 81% sensitivity to predict ARDS from baseline data @RheumNow #EULAR2021 Abstr#OP0288 https://t.co/tHlPzeX9He
Richard Conway RichardPAConway ( View Tweet)
RheumNow’s expanded coverage of the #EULAR2021 Annual meeting is sponsored in part by Novartis, Bristol Myers Squibb, Janssen. All content chosen by RheumNow & its faculty.
Dr. John Cush RheumNow ( View Tweet)
Check out our Lupus content from #EULAR2021 at RheumNow.
https://t.co/Gmh4sFv4Jl https://t.co/yBkbeMn0Yd
Links:
Dr. John Cush RheumNow ( View Tweet)
#OP0227 #TYK2 inhibitor deucravacitinib showed good efficacy in #PsA patients vs. placebo in phase 2 16weeks
Primary endpoint ACR20
12mg: 62.7%
6mg: 52.9%
PLC: 31.8%
+ well tolarated: no serious adverse events
#EULAR2021 @RheumNow https://t.co/6SFqWd79db
Paul Studenic Stiddyo ( View Tweet)
Prospective analysis #OP0220 showed that PsA pt age, dz duration and activity level at tx initiation have ⬇️ with TNFi over the past 20 years. TNFi retention rates have ⬇️ while remission rates have ⬆️ (notably those in 1st yr tx) #EULAR2021 @RheumNow https://t.co/gnKRfvbHPQ https://t.co/PRunGIxMwx
Dr. Rachel Tate uptoTate ( View Tweet)
IL-17i expressed in overuse tendinopathy. Secukinumab for tx of rotator cuff tendinopathy?
⭐️Phase II study - no difference in rotator cuff score (WORC) vs placebo
⭐️no difference in pain score
Abs#POS0022
#EULAR2021 @RheumNow
Robert B Chao, MD doctorRBC ( View Tweet)
Pregnancy is a minefield for RA pts:
dx activity➡️preg risk
PNL➡️preg risk, but dx activity proxy?
bring on Swedish/Danish linked data:
1739 RA preg matched 1:10
⬆️pre-term/SGA risk with bDMARDs/PNL
adj for dx activity: less bad, but still concern?
OP0210 #EULAR2021 @RheumNow https://t.co/AlwFtmGcZH
David Liew drdavidliew ( View Tweet)
Ever wonder why one drug works in a pt & not another? Study of bio markers in PsA from RCT of #upadacitinib vs #adalimumab shows diff pathways affected by each drug & some overlap too @RheumNow #EULAR2021 @eular_org OP0030 https://t.co/WifrVOIMkW
Janet Pope Janetbirdope ( View Tweet)
UPSTREAM results #OP0223 suggest that the newly developed and preliminary validated MSKUS PsA dz activity and damage scores could be used in observational and controlled trials.
#EULAR2021 @RheumNow https://t.co/Tw7OWyMcgX https://t.co/WiT0yGwVqK
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
In the ESPOIR cohort of 813 RA followed for 10 years, polypharmacy associated w/ less DAS28 ESR Remission at 5 (45.0% in vs. 56.3% (p=0.03)) and 10 yrs (32.5% vs. 67.5% (p=0.06)) BUT no longer significant when adjusted for comorbidities!
#EULAR2021 @Rheumnow #OP0098 https://t.co/pSrr1dzKFP
Aurelie Najm AurelieRheumo ( View Tweet)
Double hit”: #OP0015
Phase IIA ABBV-3373 (Adalimumab linked to GC receptor modulator GRM) vs. PBO and historic ADA show promising results with a satisfactory safety profile compared to ADA. A potential new IV drug in RA! #EULAR2021 @Rheumnow https://t.co/mqLtXx9zBI
Aurelie Najm AurelieRheumo ( View Tweet)
Acute Coronary Syndrom incidence in > 24,000 RA from Nordic registers followed up to 5 yrs = 5.5/1000 pyrs. After 5yrs RTX show > risk of ACS compared to ETA. In patient with >= 2 previous DMARDs ABA, INF and RTX > risk of ACS compared to ETA.
#EULAR2021 @Rheumnow #OP0114 https://t.co/MjW9LI2cjt
Aurelie Najm AurelieRheumo ( View Tweet)
Patients with RA > 70yo and risk of severe infection: which therapeutic strategy is the safest?
#EULAR2021 @Rheumnow #OP0116
Aurelie Najm AurelieRheumo ( View Tweet)
Dr Yoshida analyze data from US registry 40,721 RA patients. High 2.11 [1.13, 3.96] and moderate 1.97 [1.13, 3.43] CDAI associated w/ > HR of major adverse CV events. HRs decrease during follow up.
Tight and early disease control reduces CV burden!
#EULAR2021 @Rheumnow #OP0101 https://t.co/A0ZYE4v8uf
Aurelie Najm AurelieRheumo ( View Tweet)
In 16,448 RA from ACR’s RISE registry: no difference in disease activity TNFi and non-TNFi at 12 months. Stratified analysis: ⬆️disease activity for TNFi vs. non TNFi in patients of Black and Asian ethnicity. To be confirmed in independent cohorts.
#EULAR2021 @Rheumnow #OP0117 https://t.co/7bFnOKR9uz
Aurelie Najm AurelieRheumo ( View Tweet)
MTX or ETA which one withdraw first? @RADoctor SEAM-RA trial: PROs following withdrawal of MTX or ETN in RA patients with sustained SDAI remission receiving combination ETN+MTX. ETA > MTX for maintaining SDAI remission at W48 (49.5%-28.7% P=0.004)
#EULAR2021 @Rheumnow #OP0118 https://t.co/MSOclXGMEK
Aurelie Najm AurelieRheumo ( View Tweet)
Rheum alliance trainee survey (n=302):
87-96% report negative impact of COVID19 on Rheumatology training:
-outpatient clinics (79%)
-inpatient consultations (59%)
-formal teaching (55%)
-procedures (53%) and
-ultrasonography (36%)
#POS0051 @RheumNow #EULAR2021 @kristenyoung
Aurelie Najm AurelieRheumo ( View Tweet)
Can we predict pre-clinical RA-ILD?
@Juge_P_A ESPOIR cohort. model w/ 4 variables: male gender, older age @ diag, mean DAS-28 over follow-up and MUC5B variant ▶️ preclinical ILD after 13 years of RA w/ AUC=0.82 CI 95% (0.72-0.91) (Sens 80%, Spe 56%)
#POS0095 @Rheumnow #EULAR2021 https://t.co/bPyidNhNuO
Aurelie Najm AurelieRheumo ( View Tweet)
Curious to find out the answer?https://t.co/cXjUeQAwHD
#EULAR2021 @RheumNow #OP0012 https://t.co/7q5yZLD96v
Links:
Aurelie Najm AurelieRheumo ( View Tweet)
Very informative #EULAR2021 WIN session on MIS-C @EULAR_org
👉 Steroids early
👉 IVIg in all
👉 anticoagulant use remains variable
#Coronary aneurysms
✅ occur during acute phase in MIS-C and improve with treatment
✅ occur in the late/convalescent phase of #Kawasaki disease https://t.co/Ff3rX6u5VK
Ashima Makol MD AshimaMakol ( View Tweet)
